Lv6
1630 积分 2024-04-25 加入
Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma
14天前
已完结
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
7个月前
已完结
Pathological complete response after conversion therapy in unresectable hepatocellular carcinoma: a retrospective study
8个月前
已完结
Hepatic Resection versus Transarterial Lipiodol Chemoembolization as the Initial Treatment for Large, Multiple, and Resectable Hepatocellular Carcinomas: A Prospective Nonrandomized Analysis
10个月前
已完结
Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience
10个月前
已完结
Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma
10个月前
已完结
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
11个月前
已完结
Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy
11个月前
已关闭
TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study
11个月前
已完结
Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
11个月前
已完结
皖公网安备34019202002308
